Cannabis for Fatty Liver Disease (non-alcoholic) aka (Steatosis)

Studies and Information on Cannabis for Fatty Liver Disease (non-alcoholic) aka (Steatosis)

Globally nonalcoholic fatty liver disease is the most common chronic liver disease known to date. Symptoms include significant fat build up in and around the liver without a history of alcohol abuse. The condition is also known as steatosis or steatohepatitis.

Ratings for Cannabis and Fatty Liver Disease (non-alcoholic) aka (Steatosis)

Rated 1.5 / 5 (How Ratings Work)


Possibility of efficacy for cannabis in treatment of fatty liver disease (non-alcoholic) aka (steatosis).
Based on 2 Studies from 2016 - 2017

Studies on Cannabis and Fatty Liver Disease (non-alcoholic) aka (Steatosis)


Study Name, Description & Year

Rating

Beta-caryophyllene Protects Against Alcoholic Steatohepatitis By Attenuating Inflammation And Metabolic Dysregulation In Mice
Animal study (mice) — 2017

2


β-Caryophyllene Attenuates Palmitate-induced Lipid Accumulation Through AMPK Signaling By Activating CB2 Receptor In Human HepG2 Hepatocytes
Laboratory test — 2016

1



View All Conditions